Actively Recruiting
Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Led by Early is Good Inc. · Updated on 2026-04-23
500
Participants Needed
3
Research Sites
161 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitoring solution.
CONDITIONS
Official Title
Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 Years and older
- Diagnosed with incident or recurrent NMIBC within the past 2 years and undergoing routine cystoscopy monitoring
- Able to provide legally effective informed consent
- Able to provide at least 30 mL of voided urine
You will not qualify if you...
- Planning to undergo radical cystectomy or chemotherapy-radiation for Urothelial Cell Carcinoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Arkansas Urology Research Center
Little Rock, Arkansas, United States, 72211
Actively Recruiting
2
Indiana University School of Medicine
Indianapolis, Indiana, United States, 46202
Actively Recruiting
3
Washington University
St Louis, Missouri, United States, 63130
Actively Recruiting
Research Team
T
Thakshila Liyanage, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here